NovoMix 30 UPGRADE (NovoMix 30 Use for Progressed Glycemic Control in Realistic Administration to DiabEtes Mellitus): A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Efficacy and Safety Study in Patients Using Biphasic Insulin Aspart 30 (NovoMix 30) for the Treatment of Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms UPGRADE
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 26 Nov 2010 Official Title amended as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.